Price
No data yet.
Social Signal Score
Revenue
$1.44B+542.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John C. Rademacher
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 7,397
- Beta
- 0.61
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.58
Financials
Revenue
$1.44B+542.4%Net Income
$53.91MEBITDA
$106.39M+3662.0%Free Cash Flow
$192.64MEPS (diluted)
$0.35Shares Outstanding (diluted)
155.77M+442.6%Operating Expenses
$161.11MCash & Debt
$193.77MReturn of Capital
$153.01MRevenue by Segment (annual)
$5.65BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.65B | $207.59M | $1.28 |
| 2024 | $5.00B | $211.82M | $1.23 |
| 2023 | $4.30B | $267.09M | $1.49 |
| 2022 | $3.94B | $150.56M | $0.83 |
| 2021 | $3.44B | $139.90M | $0.78 |
| 2020 | $3.03B | $-8.08M | $-0.04 |
| 2019 | $2.31B | $-75.92M | $-0.49 |
| 2018 | $1.94B | $-6.12M | $-1.62 |
| 2017 | $817.19M | $-64.20M | $-2.02 |
| 2016 | $935.59M | $-42.77M | $-1.77 |
| 2015 | $982.22M | $-300.13M | $-17.45 |
| 2014 | $922.65M | $-147.47M | $-8.61 |
| 2013 | $696.47M | $-69.65M | $-4.32 |
| 2012 | $593.45M | $64.71M | $4.60 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from OPCH's reported EPS growth of -9.4% a year over 13 years.
- EPS in 5 years
- $0.78
- Implied price
- $19.54
- Return from $23.85
- -3.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $9.72 — -59.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -19.4% | -20.9% | -17.4% | -14.5% | -11.9% | -9.6% |
| -14.4% | -15.9% | -12.3% | -9.2% | -6.5% | -4.0% |
| -9.4% | -11.0% | -7.2% | -3.9% | -1.0% | 1.6% |
| -4.4% | -6.1% | -2.1% | 1.4% | 4.5% | 7.2% |
| 0.6% | -1.2% | 3.0% | 6.7% | 9.9% | 12.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Neutral
Option Care Health to Participate in Upcoming Investor Conferences BANNOCKBURN, Ill., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced that John Rademacher, CEO and Meenal Sethna, CFO, will participate in the following up coming investor conferences:
View source ↗ - Newszacks.com·8d ago·Neutral
OPCH or CHE: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Option Care (OPCH) or Chemed (CHE). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗
Earnings
Thu, Oct 29(in 8 weeks)
Consensus estimate $0.48 per share
Typical surprise +5.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.45 vs $0.43beat
- Thu, Apr 30$0.40 vs $0.37beat
- Tue, Feb 24$0.46 vs $0.46beat
- Thu, Oct 30$0.45 vs $0.43beat
- Wed, Jul 30$0.41 vs $0.40beat
- Tue, Apr 29$0.40 vs $0.36beat
Estimates and results for OPCH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OPCH officers and directors.
- Bought
- $4.5m
- Sold
- $2.2m
10 trades
3 trades
- Sullivan Timothy Pbought
- Kraemer Harry M Jansen Jrbought
- Sethna Meenalbought
- Rademacher John Charlesbought
- Pate R Cartersold
- Bavaro Michaelsold
- Kraemer Harry M Jansen Jrbought
- Wright Norman L.bought
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.